If you only skimmed headlines about Tavneos investigations and Prolia facing biosimilar pressure, Amgen might have looked like a minefield in early 2026. Investors who held Amgen from the start of the year are up 36.5%, including dividends. If you had been weighing those competing analyst views in January, how would you have judged whether pipeline momentum could outweigh regulatory risk and aging blockbusters long enough to earn that outcome?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
If the move has made Amgen harder to judge, start where the gap is still open and scan 40 high quality undervalued stocks.
The shares cost US$327 at the start of the period, and Amgen holders were effectively choosing between two very different stories written by analysts.
The bullish Narrative saw Fair Value at US$403, based on the idea that AI-enabled research, a broad late stage pipeline and expanding biosimilars could support revenue growing 7.1% a year and profit margins rising from 19.0% to 31.0% by 2028.
The bearish view set Fair Value at US$185 and focused on aging therapies, patent expiries and pricing pressure, with revenue assumed to decline 0.5% annually and margins slipping to 15.2%, even while the stock traded on a higher 27.9x P/E in that scenario.
Amgen’s Q3 2026 report showed revenue of US$10.4b and net income of US$3.9b, with net margin rising to 37.3%. That supported the bullish case that margins could expand. Regulatory heat around Tavneos and Prolia pressure pulled in the other direction and underlined the cautious view on product risk. Overall, the evidence cut both ways.
The key lesson is simple. When a thesis hinges on margin expansion, track net margin and product mix in each filing. Do not just watch headline revenue or guidance upgrades.
Amgen now trades at about US$436 after a 36.5% gain from the start of the year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level and anchors its argument on how durable newer franchises really are against legacy erosion and policy pressure.
The key question for anyone paying today’s price is what has to keep working. The thesis in that Narrative implies buyers must judge whether cardiometabolic, autoimmune, oncology and biosimilar launches can outpace loss of exclusivity and pricing pressure for years without slipping.
"The main requirement for the thesis to hold is that newer cardiometabolic, autoimmune, oncology and biosimilar products continue to offset loss-of-exclusivity declines and policy pressures on profitability. The current numbers suggest that the share price already reflects strong execution in newer franchises and high profitability, which may leave limited room for disappointment without potential share price downside."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
That is three of the list. See the full list of 24 financially solid companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com